A Randomized study to evaluate the safety, efficacy and pharmacokinetics of three dose levels (60, 75 and 100 mg/m2) of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension in women with Metastatic Breast Cancer
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 05 Apr 2017 New trial record
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics